INDEMNIFICATION AGREEMENTIndemnification Agreement • August 15th, 2019 • IMARA Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [ ] between IMARA Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • August 15th, 2019 • IMARA Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 15th day of March, 2019 by and among IMARA Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and any additional purchasers that becomes a party to this Agreement in accordance with Section 6.9 hereof, and for purposes of Sections 1, 3.1, 3.2, 3.4(b), 3.6 and 4, H. Lundbeck A/S (“Lundbeck”).
OFFICE LEASE AGREEMENT BY AND BETWEEN COLUMBIA REIT — 116 HUNTINGTON, LLC a Delaware limited liability company AND IMARA INC. a Delaware corporation 116 Huntington Avenue Boston, Massachusetts 02116Office Lease Agreement • August 15th, 2019 • IMARA Inc. • Pharmaceutical preparations • Massachusetts
THIS OFFICE LEASE AGREEMENT (this “Lease”) is dated as of May 20, 2019 (the “Execution Date”), by and between COLUMBIA REIT — 116 HUNTINGTON, LLC, a Delaware limited liability company (“Landlord”), and IMARA INC., a Delaware corporation (“Tenant”).
IMARA INC. INCENTIVE STOCK OPTION AGREEMENT GRANTED UNDER 2016 STOCK INCENTIVE PLANIncentive Stock Option Agreement • August 15th, 2019 • IMARA Inc. • Pharmaceutical preparations
IMARA Inc. NONSTATUTORY STOCK OPTION AGREEMENT GRANTED UNDER 2016 STOCK INCENTIVE PLANNonstatutory Stock Option Agreement • August 15th, 2019 • IMARA Inc. • Pharmaceutical preparations
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 15th, 2019 • IMARA Inc. • Pharmaceutical preparations • New York
This Exclusive License Agreement (this “Agreement”) is made and is effective this 11th day of April, 2016 (the “Effective Date”) between IMARA, INC., a Delaware, U.S.A. corporation (“Licensee”) and having an address at 700 Technology Square, 3rd Floor, Cambridge, MA 02139, and H. LUNDBECK A/S, a for profit corporation organized and existing under the laws of Denmark with company registration no. (CVR) 56759913 (“Licensor”) and having an address at Ottiliavej 9, DK-2500 Valby, Copenhagen, Denmark. Licensee and Licensor are each referred to as a “Party” and collectively referred to as the “Parties.”
Imara, Inc. 700 Technology Square, 3rd Floor Cambridge, MA 02139 USA Info@Imaratx.com +1 617 231-6021 www.imaratx.comLetter Agreement • August 15th, 2019 • IMARA Inc. • Pharmaceutical preparations • Massachusetts
On behalf of IMARA Inc., a Delaware corporation (the “Company”), I am very pleased to offer you this revised “letter agreement” with the Company. This letter agreement shall supersede, amend and restate in all respects the letter agreement between you and the Company dated February 26, 2019 (the “Former Letter Agreement”), provided, and for the avoidance of doubt, that nothing herein supersedes the Employee Confidentiality, Assignment and Noncompetition Agreement signed by you on March 26, 2019 (the “Restrictive Covenants Agreement”), which remains in effect, unaltered, in all respects.
Imara, Inc. 700 Technology Square, 3rd Floor Cambridge, MA 02139 USA Info@Imaratx.com + 1 617 231-6021 www.imaratx.comLetter Agreement • August 15th, 2019 • IMARA Inc. • Pharmaceutical preparations • Massachusetts
On behalf of IMARA Inc., a Delaware corporation (the “Company”), I am very pleased to offer you this revised “letter agreement” with the Company. This letter agreement shall supersede, amend and restate in all respects the letter agreement between you and the Company dated April 17, 2018 (the “Former Letter Agreement”), provided, and for the avoidance of doubt, that nothing herein supersedes the Invention and Non-Disclosure Agreement or the Non-Competition and Non-Solicitation Agreement signed by you concurrently with the Former Letter Agreement (the “Restrictive Covenant Agreements”), which remain in effect, unaltered, in all respects.
